首页> 外文期刊>The American Journal of Cardiology >Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis
【24h】

Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis

机译:严重主动脉瓣狭窄患者经导管主动脉瓣置换术与主动脉瓣置换术的Meta分析

获取原文
获取原文并翻译 | 示例
       

摘要

Transcatheter aortic valve replacement (TAVR) is a viable option in the treatment of severe aortic stenosis in patients at high risk for surgery. We sought to further investigate outcomes in patients at low to intermediate risk with aortic stenosis who underwent surgical aortic valve replacement (SAVR) versus TAVR. We systematically searched the electronic databases, MEDLINE, PubMed, EMBASE, and Cochrane for prospective cohort studies of the effects of TAVR versus SAVR on clinical outcomes (30-day mortality, all-cause mortality, stroke and myocardial infarction, major vascular complications, paravalvular regurgitation, permanent pacemaker implantation, major bleeding, and acute kidney injury). We identified 5 clinical studies, examining 1,618 patients in the TAVR group and 1,581 patients in the SAVR group with an average follow-up of 1.05 years. No difference in all-cause mortality, stroke, and myocardial infarction between the 2 approaches was found. TAVR was associated with higher rates of vascular complications, permanent pacemaker implantation, and moderate or severe paravalvular regurgitation (p <0.001 for all), whereas more major bleeding events were seen in the SAVR group (p <0.001). In conclusion, TAVR was found to have similar survival and stroke rates and lower major bleeding rates as compared with SAVR in patients at low or intermediate surgical risk. However, SAVR was associated with less pacemaker placements and paravalvular regurgitation rates. (C) 2016 Elsevier Inc. All rights reserved.
机译:经导管主动脉瓣置换术(TAVR)是治疗高手术风险患者的严重主动脉瓣狭窄的可行选择。我们试图进一步调查接受外科主动脉瓣置换术(SAVR)与TAVR的低至中度主动脉瓣狭窄风险患者的预后。我们系统地搜索了电子数据库MEDLINE,PubMed,EMBASE和Cochrane,以进行前瞻性队列研究,以研究TAVR与SAVR对临床结局的影响(30天死亡率,全因死亡率,中风和心肌梗塞,主要血管并发症,瓣膜旁炎)反流,永久性起搏器植入,大出血和急性肾损伤)。我们确定了5项临床研究,检查了TAVR组的1,618例患者和SAVR组的1,581例患者,平均随访时间为1.05年。两种方法在全因死亡率,中风和心肌梗塞方面均无差异。 TAVR与血管并发症,永久性起搏器植入以及中度或重度瓣周关闭不全的发生率较高(全部p <0.001)相关,而在SAVR组中发现的出血事件较多(p <0.001)。总之,在低或中等手术风险中,与SAVR相比,TAVR被发现具有相似的生存率和中风发生率,并且主要出血率更低。但是,SAVR与较少的起搏器放置和瓣周返流率相关。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号